Zobrazeno 1 - 10 of 128 pro vyhledávání: '"L, Mateva"'
1
Metabolic determinants of NAFLD in adults with type 1 diabetes
Autor: M. Serdarova, R. Dimova, N. Chakarova, G. Grozeva, A. Todorova, P. Tsarkova, C. Marinova, D. Popov, L. Mateva, T. Tankova
Publikováno v: Diabetes research and clinical practice. 186
To assess the main metabolic determinants of non-alcoholic fatty liver disease (NAFLD) in adult patients with type 1 diabetes (T1D).115 patients with T1D were divided into 4 groups according to NAFLD grade. NAFLD was diagnosed via transient elastogra
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::112d0f5f7c58251ebe3fe7013e837181
https://pubmed.ncbi.nlm.nih.gov/35248654
Zobrazit plný text záznamu
3
Akademický článek
Doppler Parameters of Hepatic and Renal Hemodynamics in Patients with Liver Cirrhosis
Autor: D. Popov, R. Krasteva, R. Ivanova, L. Mateva, Z. Krastev
Publikováno v: International Journal of Nephrology, Vol 2012 (2012)
Introduction. There are limited studies on simultaneous evaluation of liver and renal blood flow using Doppler methods. We evaluated and compared the changes of liver and renal Doppler US parameters in patients with liver cirrhosis according to the d
Externí odkaz: https://doaj.org/article/ca176e4df2ea42a0a1dd4adb80439b41
Zobrazit plný text záznamu
5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
6
Strategies to manage hepatitis C virus infection disease burden-Volume 4
Autor: D. S. Chen, W. Hamoudi, B. Mustapha, J. Layden, A. Nersesov, T. Reic, V. Garcia, C. Rios, L. Mateva, O. Njoya, S. A. Al-Busafi, M. K. Abdelmageed, M. Abdulla, D. Adda, O. Akin, A. Al Baqali, N. Al Dweik, K. Al Ejji, I. Al ghazzawi, S. Al Kaabi, K. Al Naamani, J. Al Qamish, M. Al Sadadi, J. Al Salman, M. AlBadri, H. E. Al-Romaihi, W. Ampofo, K. Antonov, C. Anyaike, F. Arome, A. Bane, S. Blach, M. M. Borodo, S. M. Brandon, B. Bright, M. T. Butt, I. Cardenas, H. L. Y. Chan, C. J. Chen, P. J. Chen, R. N. Chien, W. L. Chuang, D. Cuellar, M. Derbala, A. A. Elbardiny, C. Estes, E. Farag, J. Fung, I. Gamkrelidze, J. Genov, Z. Ghandour, M. Ghuloom, B. Gomez, J. Gunter, J. Habeeb, O. Hajelssedig, S. M. Himatt, I. Hrstic, C. C. Hu, C. F. Huang, Y. T. Hui, R. Jahis, D. Jelev, A. K. John, K. S. Kaliaskarova, Y. Kamel, J. H. Kao, J. Khamis, H. Khattabi, I. Khoudri, A. Konysbekova, I. Kotzev, M. S. Lai, W. C. Lao, M. H. Lee, O. Lesi, M. Li, A. Lo, C. K. Loo, B. Lukšić, A. Maaroufi, A. O. Malu, R. Mitova, R. Mohamed, M. Morović, K. Murphy, H. Nde, E. Ngige, R. Njouom, D. Nonković, S. Obekpa, S. Oguche, E. E. Okolo, O. Omede, C. Omuemu, P. Ondoa, O. Opare-Sem, S. Owusu-Ofori, R. O. Phillips, Y. N. Prokopenko, H. Razavi, D. Razavi-Shearer, K. Razavi-Shearer, B. Redae, T. Rinke de Wit, S. Robbins, L. R. Roberts, S. J. Sanad, M. Sharma, M. Simonova, T. H. Su, K. Sultan, S. S. Tan, K. Tchernev, O. T. Y. Tsang, S. Tsang, C. Tzeuton, S. Ugoeze, B. Uzochukwu, R. Vi, A. Vince, H. U. Wani, V. W. S. Wong, A. Workneh, R. Yacoub, K. I. Yesmembetov, M. Youbi, M. F. Yuen, J. D. Schmelzer
Publikováno v: Journal of viral hepatitis, 24 Suppl 2, 44-63. Wiley-Blackwell
The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets-"WHO Targets" (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e93f2ea3d677140e644d7162177dc8
https://doi.org/10.1111/jvh.12759
Zobrazit plný text záznamu
7
A Comparative Analysis of Serum Lipids in Patients with Chronic Hepatitis C, Nonalcoholic Fatty Liver Disease and Healthy Controls
Autor: Ivan Valkov, C. Marinova, L. Mateva, R. Ivanova, A. Alexiev, Dejan Jelev, Krasimir Antonov, Radina Ivanova
Publikováno v: Acta Medica Bulgarica, Vol 44, Iss 1, Pp 5-10 (2017)
Serum lipids abnormalities are widespread among patients with chronic hepatitis C (CHC), but the impact of concomitant hepatic steatosis [steatosis, nonalcoholic steatosis (NAS)], as well as distinctions between it and nonalcoholic fatty liver diseas
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fe977048ba7878a508559e811782235
https://doaj.org/article/da757f1fbc844fa797c1175315432bf8
Zobrazit plný text záznamu
8
Fighting Hepatitis C in a COVID-19 ecosystem. Public health policies are needed more than ever
Autor: Todor Kundurzhiev, Henrique Lopes, Ricardo Baptista-Leite, L. Mateva, Marieta Simonova, Diogo Franco, Dejan Jelev
Publikováno v: Repositório Científico de Acesso Aberto de Portugal
Repositório Científico de Acesso Aberto de Portugal (RCAAP)
instacron:RCAAP
Submitted by Agostinho Macau (arm@lisboa.ucp.pt) on 2021-03-16T15:35:10Z No. of bitstreams: 1 document_1_.pdf: 171858 bytes, checksum: f3ec717d85d06f3116333fcb6b1962d5 (MD5) Made available in DSpace on 2021-03-16T15:35:10Z (GMT). No. of bitstreams: 1
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd101bcb811e23b5f5c8e642fd51cf65
https://doi.org/10.15403/jgld-2794
Zobrazit plný text záznamu
9
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
Autor: Dorien Groenendaal-van de Meent, Martin den Adel, Jan Noukens, Marloes Schaddelee, A. Alexiev, Sanne Rijnders, Axel Krebs-Brown, L. Mateva
Publikováno v: Clinical Drug Investigation
Background and Objective Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in phase III development for the treatment of anaemia associated with chronic kidney disease. This study evaluated the effects of moderate hepatic impairme
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0711676a58cc009653093b6b35fe7d88
http://europepmc.org/articles/PMC4987405
Zobrazit plný text záznamu
10
Monoallelic expression of the TTR gene as a contributor to the age at onset and penetrance of TTR-related amyloidosis
Autor: Andrey Kirov, Vanyo Mitev, Mariana Gospodinova, Albena Todorova, Zornitza Pavlova, A. Alexiev, Teodora Chamova, Iglika Yordanova, Ivailo Tournev, Stayko Sarafov, Tihomir Todorov, L. Mateva
Publikováno v: Gene. 705
TTR-related amyloidosis (ATTR) is manifested in two allelic forms: familial amyloid polyneuropathy (TTR-FAP) and cardiomyopathy (TTR-FAC), both caused by mutations in the TTR gene. The most prevalent mutation in Bulgaria is p.Glu89Gln. Markedly diffe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f8ffc12bf8e685a6313aa4c2b5844f6
https://pubmed.ncbi.nlm.nih.gov/30981840
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje